RxDoctor Payments Data

Kristi Moore, DO

Internal Medicine · Eureka, MONPI 1740439199

Payments from drug & device makers

$7,641in general payments, 2019–2025

Across 438 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$865
  • Lilly USA, LLC$765
  • Novo Nordisk$724
  • Pfizer$710
  • Amgen$471
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$7,635100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,641 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$120,853
Medicare patients
288
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$130,580
JardianceEmpagliflozin86$93,825
MounjaroTirzepatide79$91,417
OzempicSemaglutide49$79,388
TrulicityDulaglutide30$41,861
FarxigaDapagliflozin Propanediol43$35,217
MyrbetriqMirabegron44$24,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,251
TradjentaLinagliptin11$15,382
LinzessLinaclotide17$15,343
Tresiba Flextouch U-100Insulin Degludec23$12,829
ArexvyRsvpref3 Antigen/As01e/Pf39$10,414
BelsomraSuvorexant17$8,705
Tresiba Flextouch U-200Insulin Degludec12$7,002
SynthroidLevothyroxine Sodium75$6,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$710$135,795141 claims
Lilly USA, LLCMounjaro, Trulicity$765$133,278109 claims
Boehringer IngelheimJardiance, Tradjenta$108$109,20897 claims
Novo NordiskOzempic$724$79,38849 claims
AstraZenecaFarxiga, Symbicort$865$39,19760 claims
GSKTrelegy Ellipta, Arexvy$129$34,66574 claims
Astellas Pharma US IncMyrbetriq$40$24,35944 claims
AbbVieLinzess, Synthroid$1,816$21,64892 claims
MerckBelsomra$66$8,70517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$4,698499 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Eureka

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →